ecrin-mdr-crcClinical2023IPD Sharing (as of October 2023): No Description: At this time, IPD sharing has not been defined and/or decided if it will be shared.Kidney NeoplasmsGynecologic CancerPancreas CancerSkin CancerSolid TumorColorectal CancerHead and Neck CancerNon Small Cell Lung CancerPancreatic NeoplasmsKidney CancerCancerGynecologic CancerKidney NeoplasmsPancreas CancerSkin CancerSolid TumorColorectal CancerNon Small Cell Lung CancerHead And Neck CancerKidney CancerPancreatic NeoplasmsCancerInterventionalhttps://newmdr.ecrin.org/Study/6564United States4Immune Checkpoint InhibitorsCapecitabineCytokineDEKADK210(EGFR)OncologyIL-2Immuno-oncologyIL-10PembrolizumabOxaliplatinInterleukin 2NivolumabImmunotherapyPaclitaxelInterleukin 10CarboplatinDEKA BiosciencesFluorouracilECRIN MDRRecruitingfalseEvaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsThis study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.2023-04-156564NCT05704985